SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

ELI LILLY & Co (New York Stock Exchange:LLY)

US · Delayed Price · Currency is USD
1124.16+0.25 (+0.02%)
 
Market Cap1.06T+49.0%
Revenue (ttm)79.67B+49.6%
Net Income26.71B+93.5%
EPS29.80+94.8%
Shares Out941.74M
PE Ratio37.66
Forward PE24.10
Dividend$6.69(0.60%)
Ex-Dividend DateAug 14, 2026
Volume2,013,187
Open1126.54
Previous Close1123.91
Day's Range1119.01 - 1138.70
52-Week Range712.05 - 1292.65
Beta0.50
AnalystsBuy
Price Target1345.40(+19.68%)
Earnings DateOct 29, 2026
+0.02% (1D)
No price history available.

About LLY

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Address
Lilly Corporate Center, Indianapolis, IN, 46285, US
Market Cap
1.06 trillion
Employees
50,000
Industrial Classification
Drug Manufacturers - General

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$15.96M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
+0.02%
5 Days
-2.30%
1 Month
-8.75%
6 Months
+12.26%
1 Year
+48.97%

$LLY stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of LLY by members of U.S. Congress

PoliticianTypeTraded
Michael RulliHouse / RSale$1.00K – $15.00KJul 1, 2026
Michael A. RulliHouse / RSale$1.00K – $15.00KJul 1, 2026
David J. TaylorHouse / RPurchase$1.00K – $15.00KFeb 25, 2026
David J. TaylorHouse / RSale$1.00K – $15.00KFeb 8, 2026
David J. TaylorHouse / RSale$1.00K – $15.00KJan 15, 2026
Michael RulliHouse / RPurchase$1.00K – $15.00KJan 2, 2026
Michael A. RulliHouse / RPurchase$1.00K – $15.00KJan 2, 2026
David J. TaylorHouse / RSale$1.00K – $15.00KDec 9, 2025

Recently reported changes in LLY holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LLY's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q32025Q42026Q12026Q22026Q3

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LLY Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LLY Revenue by Segment or Geography

LLY's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New LLY patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LLY from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LLY

ETFEst. Holding Size
VTIVanguard Morningstar Total Stock Market ETF$31.01B
VOOVanguard S&P 500 ETF$23.86B
IVViShares Core S&P 500 ETF$12.00B
SPYState Street SPDR S&P 500 ETF$10.91B
VUGVanguard Morningstar Growth ETF$10.12B
XLVState Street Health Care Select Sector SPDR ETF$6.56B

Estimated from each fund’s disclosed top holdings × AUM

LLY Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for LLY is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from LLY’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
0
Sells
3
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.